UCL spinout Ori Biotech has raised more than $100m in a series B round led by Novalis LifeSciences, just over a year after closing a $30m series A round.

Ori Biotech, a UK-based cell and gene therapy manufacturing technology spinout of University College London, picked up more than $100m in its series B round led by Novalis LifeSciences on Tuesday. Puhua Capital and Chimera Abu Dhabi also took part in the round, as did returning investors Amadeus Capital Partners, Delin Ventures, Northpond Ventures and…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.